Read by QxMD icon Read

Preoperative chemotherapy of NSCLC

Shan Xian Guo, Yan Jian, Ying Lan Chen, Yun Cai, Qing Yuan Zhang, Fang Fang Tou
Neoadjuvant Chemotherapy has been used for the stage III of non-small cell lung cancer (NSCLC) and has shown good clinical effects. However, the survival benefits of radiation therapy added in induction regimens remains controversial. We therefore conducted a meta-analysis of the published clinical trials to quantitatively evaluate the benefit of preoperative chemoradiotherapy. After searching the database of Pubmed, CNKI, EMBASE, ESMO, The Cochrane Library databases, The American Society of Clinical Oncology and Clinical Trials...
September 28, 2016: Scientific Reports
X Duan, Y Cui, H Li, G Shi, B Wu, M Liu, D Chang, T Wang, Y Kong
BACKGROUND: Serum carcinoembryonic antigen (CEA) and the soluble fragment of cytokeratin 19 (CYFRA 21-1) are supposed to have a prognostic role in patients with nonsmall cell lung cancer (NSCLC) after surgery, but it has not been used as an adjunct to the tumor-node-metastasis (TNM) staging system to provide therapy options for patients with pathological Stage I NSCLC. This study was designed to investigate the effect of serum levels of CEA and CYFRA 21-1 before and after surgery on the prognosis of patients with Stage I NSCLC...
December 2015: Indian Journal of Cancer
Ryu Kanzaki, Hisamichi Naito, Kazuyoshi Kise, Kazuhiro Takara, Daisuke Eino, Masato Minami, Yasushi Shintani, Soichiro Funaki, Tomohiro Kawamura, Toru Kimura, Meinoshin Okumura, Nobuyuki Takakura
BACKGROUND: PSF1 (Partner of SLD Five 1) is an evolutionarily conserved DNA replication factor that is part of the GINS (Go, Ichi, Nii, and San) complex . The objective of this study was to evaluate the relationship between PSF1 expression and prognosis in patients with non-small cell lung cancer (NSCLC) treated with surgery following preoperative chemotherapy or chemoradiotherapy. METHODS: Sixty-nine patients with NSCLC treated with surgery following preoperative chemotherapy or chemoradiotherapy who did not achieve pathologic complete response were enrolled...
July 5, 2016: Annals of Surgical Oncology
Yifan Zheng, Michael T Jaklitsch, Raphael Bueno
Locally advanced (stage IIIA) non-small cell lung cancer (NSCLC) is confined to the chest, but requires more than surgery to maximize cure. Therapy given preoperatively is termed neoadjuvant, whereas postoperative therapy is termed adjuvant. Trimodality therapy (chemotherapy, radiation, and surgery) has become the standard treatment regimen for resectable, locally advanced NSCLC. During the past 2 decades, several prospective, randomized, and nonrandomized studies have explored various regimens for preoperative treatment of NSCLC...
July 2016: Surgical Oncology Clinics of North America
Hongliang Ren, Wengui Xu, Jian You, Xiuyu Song, Hui Huang, Ning Zhao, Xiubao Ren, Xinwei Zhang
BACKGROUND: Lung cancer is the leading cause of cancer death in men and women in the world, more than one-half of cases are diagnosed at a advanced stage, and the overall 5-year survival rate for lung cancer is 18%. Lung cancer is divided into non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC). Approximately 80%-85% of cases are NSCLC which includes three main types: adenocarcinoma (40%), squamous cell carcinoma (SCC) (20%-30%), and large cell carcinoma (10%). Although therapies that target driver mutations in adenocarcinomas are showing some promise, they are proving ineffective in smoking-related SCC...
April 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
W Schreiner, W Dudek, S Lettmaier, S Gavrychenkova, R Rieker, R Fietkau, H Sirbu
The role of surgical lung resection following neo-adjuvant radio-chemotherapy (RCT) in patients with locally advanced non-small cell lung cancer (NSCLC) is yet not clearly defined. The aim of our study was to analyze the postoperative survival and to identify relevant prognostic factors. 46 patients underwent curative resections after neo-adjuvant RCT for locally advanced NSCLC (IIIA/IIIB) between February 2008 and February 2015. A retrospective data analysis regarding preoperative regression status, perioperative mortality, postoperative survival, patho-histological remission, relapse pattern and other prognostic factors was performed...
June 2016: Zentralblatt Für Chirurgie
Frederik Enders, Christoph Geisenberger, Christine Jungk, Justo Lorenzo Bermejo, Rolf Warta, Andreas von Deimling, Christel Herold-Mende, Andreas Unterberg
OBJECTIVE: Brain metastases (BMs) are the most common malignant brain tumors in adults. Despite multimodal treatment options such as microsurgery, radiotherapy and chemotherapy, prognosis still remains very poor. Non-small cell lung cancer (NSCLC) constitutes the most common source of brain metastases. In this study, prognostic factors in this patient population were identified through an in-depth analysis of clinical parameters of patients with BMs from NSCLC. PATIENTS AND METHODS: Clinical data of 114 NSCLC cancer patients who underwent surgery for BMs at the University Hospital Heidelberg were retrospectively reviewed for age, gender, type of treatment, time course of the disease, presence of neurologic symptoms, Karnofsky Performance Status (KPS), smoking history, presence of extracranial metastases at initial diagnosis of NSCLC, number, location and size of brain metastases...
March 2016: Clinical Neurology and Neurosurgery
Yoichi Ohtaki, Kimihiro Shimizu, Kyoichi Kaira, Toshiteru Nagashima, Kai Obayashi, Seshiru Nakazawa, Seiichi Kakegawa, Hitoshi Igai, Mitsuhiro Kamiyoshihara, Masahiko Nishiyama, Izumi Takeyoshi
PURPOSE: The aim of this study was to identify risk factors for recurrence in non-small cell lung cancer (NSCLC) patients with lymph node metastases after surgical resection. METHODS: We reviewed 66 consecutive patients with surgically resected NSCLC who had pathologically proven positive lymph nodes (pN1 or pN2). All patients underwent a preoperative 2-[(18)F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) evaluation. We analyzed the recurrence-free survival (RFS) and recurrence-free proportion (RFP) according to the clinicopathological factors...
October 2016: Surgery Today
Se-Jun Park, Chong-Suh Lee, Sung-Soo Chung
BACKGROUND CONTEXT: A number of studies have reported favorable surgical results for metastatic spinal tumors from various solid tumors. However, there are few data available on metastatic spinal cord compression (MSCC) from lung cancer despite its considerable frequency. PURPOSE: The study aims to present the functional outcomes, survival time, and complications after surgical treatment for MSCC from non-small cell lung cancer (NSCLC). STUDY DESIGN/SETTING: This is a longitudinal observational study...
March 2016: Spine Journal: Official Journal of the North American Spine Society
Haitang Yang, Feng Yao, Yang Zhao, Heng Zhao
BACKGROUND: To assess the effect of preoperative neoadjuvant therapy on resectability, downstaging, and the prognosis in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: Eighty-four patients who underwent resections after induction therapy [76 with neoadjuvant chemotherapy (CTx) and 8 with induction chemoradiotherapy (CRTx)] for clinically evident [larger than 1 cm on computed tomography (CT)] and pathologically confirmed ipsilateral N2 positive NSCLC (stage IIIA) between January 2009 and July 2013 were reviewed retrospectively...
September 2015: Journal of Thoracic Disease
Zuen Ren, Shijie Zhou, Zhidong Liu, Shaofa Xu
BACKGROUND: The efficacy of induction treatment plus surgery for improving postoperative survival in patients with non-small-cell lung cancer (NSCLC) in stages IIIA-N2 is controversial, especially compared with the combined chemotherapy and radiotherapy. We therefore performed a systematic review and meta-analysis of the published phase III randomized clinical trials (RCTs) to quantitatively evaluate the survival benefit of preoperative induction treatment vs. combined chemoradiotherapy...
August 2015: Journal of Thoracic Disease
Guangliang Qiang, Rui Xu, Jie Liu, Jue Yan, Yanyan Xu, Jinxi Di, Jiping Da, Chaoyang Liang, Bin Shi, Yongqing Guo, Deruo Liu
OBJECTIVE: To analyze the prognostic impact of preoperative (18)F-fluorodeoxyglucose (FDG) PET-CT on postoperative recurrence in patients with completely resected stage I non-small cell lung cancer (NSCLC). METHODS: The clinic data of 182 patients with stage I NSCLC who underwent (18)F-FDG PET-CT scan before surgical resection between June 2005 and June 2012 were reviewed retrospectively. There were 121 male and 61 female patients, with an average age of 68 years (range from 34 to 85 years)...
July 1, 2015: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Heli Yang, Liang Dai, Pei Li, Luyan Shen, Wanpu Yan, Mengying Fan, Keneng Chen
BACKGROUND AND OBJECTIVE: It has still been controversial to treat N2-IIIa non-small cell lung cancer (NSCLC) patients by surgery or non-surgery. We retrospectively analysed the survival of 121 stage N2-IIIa NSCLC patients treated with surgery and explored their postoperatively long-term prognostic factors. METHODS: All of 1,290 patients in Beijing Cancer Hospital underwent resection by single-surgeon-team, among which 121 cases with stage N2-IIIa were enrolled in the study...
August 2015: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Mara B Antonoff, Wayne L Hofstetter, Arlene M Correa, Jennifer M Bell, Boris Sepesi, David C Rice, Ara A Vaporciyan, Garrett L Walsh, Reza J Mehran, Stephen G Swisher, Bryan F Meyers
BACKGROUND: Management of superior sulcus non-small cell lung cancer (NSCLC) continues to evolve, with preoperative chemoradiotherapy (CXRT) followed by surgical intervention supported by several studies. Rates of pathologic complete response (pCR) have varied, and previous attempts to identify clinical predictors of pCR have been unsuccessful. We analyzed our experience with resected superior sulcus NSCLC to elucidate clinical features suggestive of pCR among patients after preoperative treatment...
January 2016: Annals of Thoracic Surgery
Pamela Samson, Aalok Patel, Traves D Crabtree, Daniel Morgensztern, Cliff G Robinson, Graham A Colditz, Saiama Waqar, Daniel Kreisel, A Sasha Krupnick, G Alexander Patterson, Stephen Broderick, Bryan F Meyers, Varun Puri
BACKGROUND: Improved survival of patients with early-stage non-small cell lung cancer (NSCLC) undergoing resection at high-volume centers has been reported. However, the effect of institution is unclear in stage IIIA NSCLC, where a variety of neoadjuvant and adjuvant therapies are used. METHODS: Treatment and outcomes data of clinical stage IIIA NSCLC patients undergoing resection as part of multimodality therapy was obtained from the National Cancer Database. Multivariable regression models were fitted to evaluate variables influencing 30-day mortality and overall survival...
November 2015: Annals of Thoracic Surgery
Björn Már Fridriksson, Steinn Jónsson, Gudrún Nína Oskarsdottir, Andri Wilberg Orrason, Helgi J Ísaksson, Tomas Gudbjartsson
OBJECTIVE: Pancoast tumors are lung carcinomas that invade the apical chest wall and surrounding structures. Treatment is complex and often involves surgery together with radio- and chemotherapy. We studied the outcome of surgical resection for Pancoast tumors in Iceland. MATERIALS AND METHODS: A retrospective study including all patients that underwent resection of a Pancoast tumor with curative intent in Iceland in the years 1991-2010. Data on symptoms, complications, TNM-stage, relapse and survival were analyzed...
July 2015: Læknablađiđ
Hua Zhang, Honggang Xia, Lianmin Zhang, Bin Zhang, Dongsheng Yue, Changli Wang
BACKGROUND: Our aim was to determinate the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in primary operable patients with non-small cell lung cancer (NSCLC). METHODS: Six hundred seventy-eight NSCLC patients were enrolled in this study. The prognostic significance of both markers was determined by both univariate and multivariate Cox survival analysis. The cut-off value for NLR and PLR was selected by using receiver operating characteristic curve analysis...
September 2015: American Journal of Surgery
Xinchun Duan, Yong Cui, Min Gong, Feng Tian, Guan Shi, Bingqun Wu, Mingliang Liu, Jiayun Guo, Yuanyuan Kong
BACKGROUND AND OBJECTIVE: Serum carcinoembryonic antigen (CEA) and the soluble fragment of cytokeratin 19 (CYFRA21-1) are important tumor markers (TMs) in the preoperative examination of patients with non-small cell lung cancer (NSCLC). However, the prognostic role of these markers in NSCLC patients remains controversial. The aim of the study was to investigate the clinical significance of serum CEA variances and CYFRA21-1 levels for the prognosis of NSCLC patients following surgery. METHODS: This retrospective study investigated the clinical records and follow-up sessions of 175 patients with NSCLC who accepted surgery and adjuvant chemotherapy...
June 2015: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
Sung Hwan Kim, Jong Hoon Lee, Guk Jin Lee, Songmi Jeong, Yoo-Kang Kwak, Hoon-Kyo Kim, Deog Gon Cho, Young Ha Park, Mina Yu, Sei Chul Yoon
We evaluate the correlation of clinical staging on positron emission tomography-computed tomography (PET-CT) and pathologic staging and the prognostic value of PET-CT after induction chemotherapy in patients with locally advanced nonsmall cell lung cancer (NSCLC). We analyzed 42 cases of clinical stage IIIA-N2 NSCLC who receive 2 to 4 cycles of preoperative chemotherapy with or without radiation followed by curative resection. The maximum standard uptake value (SUVmax) of the suspected lesion on PET-CT was recorded...
June 2015: Medicine (Baltimore)
Denis Moro-Sibilot, Clarisse Audigier-Valette, Patrick Merle, Elisabeth Quoix, Pierre-Jean Souquet, Fabrice Barlesi, Christos Chouaid, Olivier Molinier, Jaafar Bennouna, Armelle Lavolé, Julien Mazières, Anne-Claire Toffart, Alexandra Langlais, Franck Morin, Gérard Zalcman
INTRODUCTION: This study compared the efficacy of docetaxel alone vs. docetaxel plus cisplatin/carboplatin in resected NSCLC patients relapsing after preoperative, adjuvant, or perioperative platinum-based chemotherapy. MATERIALS AND METHODS: Patients were randomly assigned to receive docetaxel plus cisplatin/carboplatin (Arm A) or docetaxel alone (Arm B). Primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate at 6 weeks, toxicity, quality of life, and overall survival (OS)...
August 2015: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"